SOURCES SOUGHT
A -- Animal Models of Infectious Diseases
- Notice Date
- 7/23/2008
- Notice Type
- Sources Sought
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Office of Acquisitions, 6700 B Rockledge Room 3214 MSC7612, Bethesda, Maryland, 20892-7612
- ZIP Code
- 20892-7612
- Solicitation Number
- RFP-NIH-NIAID-DMID-AI2008041
- Archive Date
- 8/22/2008
- Point of Contact
- Brian E Jamieson,, Phone: 301-496-0612, Yvette R Brown,, Phone: 301-496-0612
- E-Mail Address
-
bjamieson@niaid.nih.gov, ybrown@niaid.nih.gov
- Small Business Set-Aside
- N/A
- Description
- THIS NOTICE IS FOR INFORMATION AND PLANNING PURPOSES ONLY. THIS IS NOT A REQUEST FOR PROPOSAL AND DOES NOT COMMIT THE GOVERNMENT TO AWARD A CONTRACT NOW OR IN THE FUTURE. NO SOLICITATION IS AVAILABLE AT THIS TIME. BASED ON CAPABILITY STATEMENTS RECEIVED IN RESPONSE TO THIS SOURCES SOUGHT ANNOUNCEMENT THIS ACQUISITION MAY BE SOLICITED AS A 100% SMALL BUSINESS SET-ASIDE. ALL SMALL BUSINESS ORGANIZATIONS (SB, SDB, WOSB, HUBZone, VOSB, and SDVOSB) ARE ENCOURAGED TO RESPOND TO THIS NOTICE. SMALL BUSINESS ORGANIZATIONS MUST HAVE THEIR SIZE STATUS CERTIFIED BY THE SMALL BUSINESS ADMINISTRATION. ALL SMALL BUSINESSES ARE ENCOURAGED TO RESPOND. THE NAICS CODE IS 541711 WITH A SIZE STANDARD OF 500 EMPLOYEES. NIAID’s role in developing medical products to counter emerging, re-emerging and other infectious diseases, as well as agents of bioterrorism, is part of a larger national strategy, involving multiple governmental agencies. As such, NIAID supports integrated efforts in basic and applied research, product development, and technology development based on national priorities for medical products. Since 2001, NIAID has established a comprehensive infrastructure with extensive resources that support all levels of biodefense research. With this solid framework of research and product development resources for biodefense in place, NIAID is now transitioning this infrastructure to provide the flexibility required to meet the challenges of emerging, re-emerging and other infectious diseases in addition to biodefense. The use of animal models helps advance our understanding of infectious diseases as well as the development of therapeutics and vaccines. For example, animal models are used to evaluate product candidates; provide data in support of Investigational New Drug (IND) applications; guide the selection of human dose levels and the design of clinical studies/trials; and provide pivotal efficacy data for products to be licensed under FDA’s “Animal Efficacy Rule” (21 CFR 314.610 and 601.91), when clinical trials are not ethical or feasible. In addition, for emerging and rare diseases, understanding the disease in animals may provide relevant information when little can be learned directly from humans. Therefore, DMID is committed to developing and providing animal models to benefit the research community and public health. For the most part, animal model services and other research resources are currently provided through multiple, specialized programs. DMID now seeks to adopt an integrated approach to the provision of services and resources by creating unified, comprehensive, coordinated programs. This strategy is being employed to: advance science by promoting cross-fertilization across and within disciplines and approaches; serve the research community more conveniently; achieve efficient use of resources through economy of scale and avoidance of duplication; and provide the flexibility needed to respond to changing priorities. Accordingly, DMID is establishing the Animals Models of Infectious Diseases program, which will utilize the Indefinite Delivery, Indefinite Quantity (IDIQ) contract mechanism. Under IDIQ contracts, base contract awards are made to multiple offerors that successfully propose a general approach to the technical requirements of the solicitation, providing a guaranteed minimum award. Task orders for specific tasks requiring specialized expertise are solicited and funded within the program Contractor pool. DMID is replacing multiple pathogen or class specific solicitations with one broad IDIQ solicitation for multiple contracts to cover all areas of current and potential future interests. Animal models currently covered by existing pathogen-specific contracts will not be re-competed separately upon completion; however, they could be awarded as task orders under this program, upon expiration of those contracts. DMID is also establishing the Microbiology and Infectious Diseases Biological Research Resources (MID-BRR) program, which will serve as a central repository for microbiology and infectious disease researchers. The Animal Models of Infectious Diseases program will ensure a supply for the MID-BRR of pathogens that must be grown in animals and reagents integral to research on these organisms. This acquisition will provide for the following services: 1.Part A - Small Animal Models – Will support the development and use of small animal models for routine screening and early efficacy testing for products against a wide range of pathogens. 2.Part B - GLP Small Animal Models – Will support the refinement and use of existing small animal models in preparation for the conduct of GLP studies, as well as GLP testing of products against a wide range of pathogens. 3.Part C - Non-Human Primate Models – Will support the development, refinement and use of non-human primate models, and may include both GLP and non-GLP studies, for testing products against a wide range of pathogens. 4.Part D - Nontraditional Animal Models – Will support the development, refinement and use of non-traditional animal models, and may include both GLP and non-GLP studies, for testing products against a wide range of pathogens. For the purposes of this acquisition: •Small animals (Parts A and B) are defined as traditional small laboratory animal species, such as mice, rats, guinea pigs, hamsters, ferrets, chinchillas, and rabbits. •Non-human primates (Part C) include various species, such as macaques, including Chinese and Indian rhesus macaques (Macaca mulatta), cynomyologous macaques (Macaca fascicularis), and pig-tailed macaques (Macaca nemestrina), etc. Excluded are baboons and chimpanzees. •Nontraditional animals (Part D) are defined as specialty laboratory animal species not covered in Small Animal or Non-Human Primate Models (Parts A – C), which may have requirements not met in typical biomedical laboratory animal facilities, such as armadillos, woodchucks, snails, other invertebrates, and goats, swine, horses, cattle, etc. •Products to be evaluated in these animal models are broadly defined to include vaccines and other prevention strategies (e.g. microbicides), therapeutics targeting the host or the pathogen, including immunotherapeutics, and diagnostics. Products will be provided to the Contractor by the Project Officer or a third party after Project Officer approval. •Pathogens of interest must be pathogens of human concern and not only of animal concern; however surrogate human pathogen/animal combinations may be used for diseases where human pathogens cannot be studied in animal models. •Pathogens are defined as bacteria, viruses, parasites, fungi, toxins, and other agents such as prions, including NIAID Category A, B and C Priority Pathogens (http://www3.niaid.nih.gov/topics/BiodefenseRelated/Biodefense/research/CatA.htm). •Reagents are defined as biochemical, genomic, molecular, cellular, and immunologic materials integral to research on these pathogens. Capability statements submitted as a result of this announcement should demonstrate the offerors’ qualifications and experience, specifically providing evidence as to their capability to perform this requirement, with particular attention to the following: Technical Capability: adequacy and appropriateness of the general technical approach to animal model studies, to include conduct of product efficacy studies, animal model development, and supportive measurements (immunological, pharmacological, clinical, pathological, etc.); technical approach to pathogen production and characterization, including overall understanding of the pathogen and its behavior in animal models. In addition, capability to comply with Good Laboratory Practices (21 CFR Part 58) will be evaluated for Part B, Part C and Part D. Personnel and Project Management: adequacy, appropriateness and relevance of expertise, experience, qualifications, and availability of the key professional and technical staff with a project of similar size, scope, and complexity; adequacy and appropriateness of proposed organization and staffing to ensure efficient planning, initiation, implementation, conduct, and completion of all activities, including plans for communication and sharing of research resources. Facilities, Equipment and other Resources: availability of adequate, accredited animal facilities, with biocontainment appropriate for the pathogens proposed; availability of equipment necessary for the proposed animal studies; and adequacy of institutional biosafety program. Past Performance: Past performance is considered essential. In addition to demonstrating that they have met the above qualifications, interested parties must identify at least three other projects of similar size and complexity. All capable small business organizations are encouraged to submit capability statements based on this announcement. Interested organizations should submit two copies of their capability statement addressing each of the areas cited above. Any proprietary information should be so marked. Written capability statements should be received by the Contracting Officer by August 7, 2008. Please reference the solicitation number on all related correspondence. No collect calls will be accepted. Facsimile and e-mail transmissions will be accepted. Any proprietary information should be so marked (see Government-Wide Numbered Note 22).
- Web Link
-
FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=df577c9205eabdf6367ab4b3e041841d&tab=core&_cview=1)
- Record
- SN01621382-W 20080725/080723223851-df577c9205eabdf6367ab4b3e041841d (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |